Open Access

REVIEW

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR–T) cell immunotherapy

ZHENGYI WANG^1,*, LIANG ZHOU¹, XIAOYING WU²

1 Department of Institute of Laboratory Animal Sciences, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China
2 Ministry of Education and Training, Chengdu Second People’s Hospital, Chengdu, China

* Corresponding Author: ZHENGYI WANG. Email:

Oncology Research 2024, 32(9), 1479-1516. https://doi.org/10.32604/or.2024.048564

Received 12 December 2023; Accepted 28 March 2024; Issue published 23 August 2024

Abstract

Chimeric antigen receptor T-cesll therapy (CAR–T) has achieved groundbreaking advancements in clinical application, ushering in a new era for innovative cancer treatment. However, the challenges associated with implementing this novel targeted cell therapy are increasingly significant. Particularly in the clinical management of solid tumors, obstacles such as the immunosuppressive effects of the tumor microenvironment, limited local tumor infiltration capability of CAR–T cells, heterogeneity of tumor targeting antigens, uncertainties surrounding CAR–T quality, control, and clinical adverse reactions have contributed to increased drug resistance and decreased compliance in tumor therapy. These factors have significantly impeded the widespread adoption and utilization of this therapeutic approach. In this paper, we comprehensively analyze recent preclinical and clinical reports on CAR–T therapy while summarizing crucial factors influencing its efficacy. Furthermore, we aim to identify existing solution strategies and explore their current research status. Through this review article, our objective is to broaden perspectives for further exploration into CAR–T therapy strategies and their clinical applications.

---

Graphic Abstract

---

Keywords

---